University of Texas: Combination of Chemotherapy and Blinatumomab Improves Survival for Patients With B-Cell Acute Lymphoblastic Leukemia
December 07, 2020
December 07, 2020
HOUSTON, Texas, Dec. 7 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphob . . .
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphob . . .